ALZNHealthcare · BiotechnologyThe 1 Wall Street analysts covering Alzamend Neuro, Inc. hold a median 12-month price target of $26 — +1840.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Alzamend Neuro, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (8): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ALZN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1840.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | Ascendiant Capital | Maintains | Buy | $25 → $26 |
| 22 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Dec 2025 | Ascendiant Capital | Maintains | Buy | $42 → $28 |
| 25 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 21 Aug 2025 | Ascendiant Capital | Maintains | Buy | — |
| 17 Mar 2025 | Ascendiant Capital | Maintains | Buy | — |
| 16 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 11 Nov 2024 | Ascendiant Capital | Maintains | Buy | — |
| 12 Apr 2023 | Maxim Group | Initiates | Buy | $1.50 |
| 1 Oct 2021 | Ascendiant Capital | Initiates | Buy | $8.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALZN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Alzamend Neuro, Inc. returned −47.0% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 68% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alzamend Neuro, Inc. has a market value of $6.5M and an enterprise value of −$980K.
Revenue in the twelve months to 31 July 2026: $0.0.
Net income over the same four quarters: −$9.1M.
Free cash flow in the twelve months to 31 July 2026: −$6.8M.
Trailing P/E: −0.5×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alzamend Neuro, Inc. employs 4 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alzamend Neuro, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alzamend Neuro was upgraded to Zacks Rank #2 (Buy), which the source says reflects growing optimism about its earnings prospects.
Why it matters — ALZN watchers may note the upgrade as an indication of improved optimism about the company’s earnings prospects.
Alzamend Neuro announced that an abstract reporting resting-state functional magnetic resonance imaging (fMRI) findings for AL001, its novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the Society for Neuroscience annual meeting held November 14–18, 2026, in Washington, DC. The poster, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI," will be presented in the Neuropsychiatric Disorders session (PSTR337) on Wednesday, November 18, 2026.
Why it matters — The acceptance of AL001's Phase 1/2A brain network data for presentation at a major neuroscience conference highlights independent scientific interest in the company's lead candidate and its clinical findings.
Alzamend Neuro announced that an abstract reporting pharmacokinetic imaging data for AL001, its novel organic lithium drug candidate, was accepted for an oral presentation at the ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR, to be held September 28–October 1, 2026 in Barcelona, Spain. The abstract, titled "Pharmacokinetics Imaging of Lithium at 7T – Results from a Phase 1/2A Clinical Trial with a Novel Organic Lithium Salt," was selected following competitive review and will be presented in the Proffered Papers oral session on September 29, 2026.
Why it matters — The acceptance of this first-of-its-kind Phase 1/2A pharmacokinetic imaging data for oral presentation at a major scientific workshop provides independent recognition and visibility for Alzamend's AL001 program.
Alzamend Neuro announced the initial closing of a Securities Purchase Agreement with Ault Lending, receiving $7.5 million in gross proceeds from the first tranche of its newly designated Series D Convertible Preferred Stock. The agreement provides for up to $25 million in total funding, with up to $17.5 million available through subsequent tranche closings to support clinical programs and working capital needs.
Why it matters — Alzamend watchers would want to know about the new financing arrangement, which provides initial capital and a potential source of additional funds for the company's clinical programs.
The 1 Wall Street analysts covering Alzamend Neuro, Inc. have a median 12-month price target of $26, with estimates ranging from $26 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Alzamend Neuro, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alzamend Neuro, Inc. 33 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Alzamend Neuro, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1840.3% from the last close, and Ticker Nerd's factor model ranks Alzamend Neuro, Inc. 33 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alzamend Neuro, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALZN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $26 over the next 12 months.
Alzamend Neuro, Inc. returned -47.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders.
The most recent item we track (Zacks Investment Research, 8 Oct 2026): "Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?". Alzamend Neuro was upgraded to Zacks Rank #2 (Buy), which the source says reflects growing optimism about its earnings prospects.
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and psychiatric disorders. Alzamend Neuro’s current pipeline centers on AL001, a patented ionic cocrystal formulation that combines lithium, proline, and salicylate, and ALZN002, a cell-based therapeutic vaccine candidate designed to help restore the immune system’s ability to combat Alzheimer’s disease. The company is working across major therapeutic areas including Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. Its research and development activities are directed toward advancing novel product candidates intended to address conditions with significant unmet medical need in neuroscience and mental health. Headquartered in Atlanta, Georgia, Alzamend Neuro plays a specialized role in the biotech market as a developer of investigational therapies focused on the central nervous system and immune-based approaches to Alzheimer’s disease.
CEO Mr. Stephan Jackman · 4 employees · United States · https://www.alzamend.com
